12:00 AM
 | 
Oct 22, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Anti-oxLDL: Development discontinued

Roche disclosed in its 3Q12 earnings it will not proceed with Phase IIb development of RG7418 after both single and multiple doses of IV BI-204 in combination with standard of care missed the primary endpoint...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >